If you are one of those people who have a stake in the stocks of MRNA, well you must be on cloud nine. Since the stocks have reached a valuation that they will never reach again, you must be thinking about selling it off. And that desire must have been reinforced by Merck selling its shares in the company. But this might not be the best decision to take. For, following others while simultaneously gauging the short-term movements of your stocks is a bad combination. Give yourself some time, and think about what you really want to do. We get it- now is as good a time as any that you will get to check up on the business that underlines the stocks of Moderna. Also, you would be able to meet the expectations put before you by the stock market.
What does the market expect from MRNA Stock?
The market cap for MRNA has gone up to almost $57 billion if valued at current prices. If that were to be put into perspective, we should bring in Regeneron, a biotechnology company with a penchant for producing successful drugs. This company, in comparison, has a market cap of just $54 billion.
Remember, that the stocks of MRNA might be fluctuating in haywire, simply because the company doesn’t really have many products to sell currently. If you expect the prices to be at a particular point, Moderna needs to generate cash flows the size of Regeneron, which might take time.
But there is no reason why Moderna shouldn’t follow in the footsteps of Regeneron. And considering the marked change in the valuation of its prices, there is a huge possibility that the stocks of MRNA might earn over $3.1 billion from products- just like Regeneron.